Patent intelligence · US
US 11826315
STAT3 inhibitors
STAT3 inhibitors
Patent details — US 11826315
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 28, 2023
- Expiration
- Nov 23, 2043
- Applicant
- Tvardi Therapeutics, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K31/18, A61P, A61P11/00
Quick answer
US 11826315 (STAT3 inhibitors) is held by Tvardi Therapeutics, Inc.. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Tvardi Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/18, A61P, A61P11/00, A61P25/00, A61P31/12
More from Tvardi Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12053444
Therapeutic compounds, formulations, and uses thereof
granted -
US 12043640
Prodrugs of STAT3 inhibitors
granted -
US 11547683
Therapeutic compounds, formulations, and uses thereof
granted -
US 11077077
Therapeutic compounds, formulations, and uses thereof
granted -
US 11026905
STAT3 inhibitors
granted
Frequently asked questions
What is US patent 11826315?
US 11826315 (STAT3 inhibitors) is held by Tvardi Therapeutics, Inc.. Status: granted. Granted Nov 28, 2023. Expires Nov 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11826315?
Tvardi Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 11826315 expire?
Our index shows an expiration date of Nov 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.